← Back to Clinical Trials
Recruiting Phase 4 NCT03906617

Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

Trial Parameters

Condition Robotic Lung Surgery
Sponsor The Cooper Health System
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 34
Sex ALL
Min Age 18 Years
Max Age 90 Years
Start Date 2019-04-10
Completion 2022-04-10
Interventions
Intercostal nerve block and wound infiltration with liposomal bupivacaineIntercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone

Brief Summary

This study will assess analgesia after robotic lung surgery. Subjects will be randomized to receive wound infiltration and intercostal nerve block with either liposomal bupivacaine or bupivacaine/epinephrine + dexamethasone. Liposomal bupivacaine is a newer local anesthetic product and has not been compared to a combination of bupivacaine/epinephrine + dexamethasone in the context of pain control after robotic lung surgery.

Eligibility Criteria

Inclusion Criteria: * undergoing robotic wedge resection or lobectomy for lung mass(es) Exclusion Criteria: * emergency case * history of opiate abuse * chronic pain syndrome * intravenous drug use * chronic use of oral steroids * pregnancy * imprisonment * body weight lower than 70 kg * liver failure * uninsured patients * non-verbal patients or patients who are unable to rate their pain on a visual analogue pain scale * history of allergic reaction to any of the drugs used in the study: bupivacaine, liposomal bupivacaine, dexamethasone

Related Trials